Lannett cleared to market Xyzal Oral Solution generic

Print Friendly, PDF & Email
PHILADELPHIA — Lannett Co. has gained Food and Drug Administration approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml (0.5 mg/ml), an allergy medication.

Lannett said its product is a generic version of Xyzal Oral Solution 2.5 mg/5 ml (0.5 mg/ml) from UCB Inc.

Plans call for levocetirizine dihydrochloride oral solution to be manufactured in Carmel, N.Y., by Lannett’s Silarx Pharmaceuticals subsidiary

“The approval of levocetirizine dihydrochloride oral Solution expands our line of oral generic drugs,” stated Arthur Bedrosian, chief executive officer of Lannett.

Levocetirizine dihydrochloride oral solution is indicated for the relief of symptoms from perennial allergic rhinitis in children ages 6 months to 2 years and for the treatment of hives (chronic idiopathic urticaria) in adults and children ages 6 months and older.



Comments are closed.